Latest news with #patentdispute
Bloomberg
4 days ago
- Business
- Bloomberg
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement
CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer Inc. and BioNTech SE in the US, which will see CureVac's former collaborator GSK Plc receive as much as $500 million and 1% of royalties from future vaccine sales. The settlement comes as BioNTech looks to close the purchase of its former rival CureVac for about $1.25 billion. GSK will receive $370 million upfront, with another $130 million on the closing of the acquisition.
Reuters
5 days ago
- Business
- Reuters
CureVac settles patent dispute litigation with Pfizer and BioNTech
Aug 7 (Reuters) - CureVac ( opens new tab said on Thursday that the company and GSK (GSK.L), opens new tab have entered an agreement to a resolve patent dispute with Pfizer (PFE.N), opens new tab and BioNTech ( opens new tab related to mRNA-based COVID-19 vaccines. As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S.
Yahoo
11-07-2025
- Business
- Yahoo
Novartis loses bid to block US Entresto generic through 2026
By Blake Brittain (Reuters) -Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto before its patent expires late next year, a Delaware federal judge said on Friday. U.S. District Judge Richard Andrews rejected Novartis' argument that MSN's generic would infringe one of its patents and denied its request to block the generic from launching until after the patent expires in November 2026. Novartis told the court in a separate filing on Friday that India-based MSN may receive U.S. Food and Drug Administration approval for the generic as soon as July 16 and launch it soon after. The generic would cut into the U.S. market for Swiss-based Novartis' best-selling drug, which earned more than $7.8 billion in global revenue last year. Novartis stock was down more than 2% on Friday morning. The company said in a statement that it was disappointed and planned to appeal. Spokespeople for MSN did not immediately respond to a request for comment. Novartis had convinced the U.S. Court of Appeals for the Federal Circuit in January to halt MSN's launch of its generic until July in a separate patent case.
Reuters
11-07-2025
- Business
- Reuters
Novartis loses bid to block US Entresto generic through 2026
July 11 (Reuters) - Novartis (NOVN.S), opens new tab cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday. U.S. District Judge Richard Andrews rejected Novartis' argument, opens new tab that MSN's generic would infringe one of its patents and denied its request to block the generic from launching until after the patent expires in November 2026. Novartis told the court in a separate filing on Friday that India-based MSN may receive U.S. Food and Drug Administration approval for the generic as soon as July 16 and launch it soon after. The generic would cut into the U.S. market for Switzerland-based Novartis' best-selling drug, which earned the company more than $7.8 billion in global revenue last year according to a company report. Novartis stock was down more than 2% on Friday morning. Spokespeople for Novartis and MSN did not immediately respond to requests for comment on the decision. Novartis had convinced the U.S. Court of Appeals for the Federal Circuit in January to halt MSN's launch of its generic until July in a separate patent case.
GSM Arena
27-06-2025
- Business
- GSM Arena
Google Pixel 7 sales banned in Japan, Pixel 8 and 9 might follow
Google just lost the right to sell its Google Pixel 7 series after a recent patent dispute with Korean mobile phone company Pantech. According to a district court in Japan, Google was found guilty of infringing a patent related to LTE connectivity. Pantech filed a lawsuit against Google, arguing that the tech giant used the exact same technology described in a patent belonging to Pantech. The patent relates to how the LTE modem in Pixel phones communicates with the cell towers. The patent, however, wasn't licensed under fair and reasonable conditions. As a result, the Tokyo court ruled that Pixel 7 phones should be removed from the shelves since Google refused to cooperate. The company refused to pay a reasonable royalty fee and also refused to provide data on the number of Pixel 7 phones sold in Japan. The Japanese market is very important for Google because it is the second-largest smartphone vendor in the country after Apple, surpassing the likes of Samsung and Xiaomi. Pantech is now filing another lawsuit against Google, targeting the more recent Pixel 8 and Pixel 9 series, so unless the two companies reach a compromise these two might face the same fate. Source 1 | Source 2
